Latest filing published 27 Feb 2026 for Avidity Biosciences, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Teresa McCarthy (senior executive) discloses dealings in Avidity Biosciences, Inc. to SEC (Form 4). The record holds 20 filings, for trades running from 20 January 2023 to 27 February 2026.
No open-market purchase appears, only 6 sales worth €848k. Other entries cover 6 share grants and 7 option exercises. So far in 2026, the count stands at no purchases and 2 sales.
The latest filing, published on 27 February 2026, reports a transaction in Avidity Biosciences, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
20 of 20 declarations